

Review Article

# The Role of Age in Intracerebral Hemorrhage: An Intricate Relationship

Camacho EJ\*, LoPresti MA\*, Bruce S, Lin D, Abraham ME, Appelboom G\*\*, McDowell M, Du Bois BG, Sathe M and Connolly ES

Cerebrovascular laboratory, Columbia University College of Physicians and Surgeons, USA

\*Corresponding author: Appelboom G, Cerebrovascular laboratory, Columbia University Medical Center, Columbia University College of Physicians and Surgeons, 630 West 168th Street, P&S 5-454,10032, New York, USA, Tel: 2123054679; Fax: 2123055544; Email: ga2294@columbia.edu

Received: August 20, 2014; Accepted: September 17, 2014; Published: September 19, 2014

## Abstract

Strokes are one of the leading causes of death in the United States, and intracerebral hemorrhage is the deadliest type of stroke. Age is a strong risk factor for intracerebral hemorrhages and it also affects the body in numerous ways—including changes to the cardiovascular and central nervous systems—that interplay with multiple risk factors. Understanding the role of age in risk and outcomes can guide treatment and future clinical trials. We reviewed the literature for intracerebral hemorrhage risk factors. This review aimed to identify the role of age, as well as characterize the most commonly used age cut-off points in the literature. Current review of the literature suggests the age cut-off for mortality and morbidity vary between 60-80 years of age, with the most common values of 65 or 70 years. In addition to age as a determinant of outcomes, it increases the risk of multiple chronic health conditions and comorbidities including hypertension, diabetes, and treatment with anticoagulants which contribute to the pathology of intracerebral hemorrhages. The interaction of these chronic conditions, age, and intracerebral hemorrhage is evident; however, the exact mechanism and extent of impact remain unclear. The ambiguity of these connections may be further obscured by the current recommendations, individual patient preferences, and literature supported trials of treatment options for aging patients.

**Keywords:** Intracerebral hemorrhage; Age; Outcome; Predictor and comorbidities

## Introduction

In the United States, stroke is the fourth leading cause of death and is one of the leading causes of long-term disability [1,2]. Intracerebral Hemorrhages (ICH) account for approximately 10-15% of all strokes and are considered to have the highest mortality rate [3]. Unlike other types of strokes, ICH does not have an effective treatment, making understanding risks factors and predictors of ICH imperative to proper risk stratification and management. One common risk associated with stroke is advancing age. Hemphill et al. created one of the first widely accepted ICH scores, and in their univariate analysis, individuals aged 80 or older were a significant independent predictor of 30-day mortality, with an odds ratio of 9.55 [4]. Natural and pathological changes that occur with aging carry numerous implications for the body, including changes to the cardiovascular and central nervous systems that interact with many other risk factors for ICH. Although there has been a recent decrease in ICH rates among patients younger than 75, rates have increased in those 75 years or older [5]. Moreover, with the trend of an aging population, there is an increase in incidence rates for many comorbidities that occur with aging, and with the associated increase in incidence rates of strokes, the potential risk of ICH among the elderly is vast. Therefore, it is the aim of this review to characterize and examine age as a predictor of ICH risk and outcomes, and identify significant markers for intervention and treatment.

## Effects of Aging

Advanced age is associated with worse clinical outcomes in many

conditions. In the case of ICH, this association may be independent or directly related to the pathology of multiple risk factors of stroke, such as hypertension. There are numerous effects of aging on the body, and most significant in the case of ICH, are age related changes of the cerebrovascular system and the aging brain.

The effect of aging on the brain's microvasculature is well-recognized, and includes decreased vascular density, micro embolic brain injury, vessel basement membrane thickening, endothelial dysfunction, and increased blood brain barrier permeability. In addition, cerebral white matter lesions known as leukoaraiosis—characterized by spongiosis, gliosis, demyelination, and capillary degeneration [6]—are seen in the elderly population with vascular risk factors and/or vascular dementia, and are thought to be related to cerebrovascular disease in this population. Systemic conditions such as hypertension and diabetes mellitus may also contribute to these changes of the cerebrovasculature. These structural changes to the brain's vasculature make the parenchyma that it supplies more susceptible to injury, which increases the risk of stroke. Pathology involving further endothelial damage, changes in vessel elasticity, or fluctuations in blood flow and pressure, implicate chronic diseases such as hypertension, atherosclerosis, diabetes, and atrial fibrillation in worsening risks of neurologic injury.

Age-related changes of gross brain volume are also well documented, with an annual loss of volume ranging from 0.2-0.5% [4], especially in regions such as the prefrontal cortex [3], and are thought to be the result of neuronal atrophy. In a study by Gottesman et al., the authors suggested that since the elderly tend to have anatomically

smaller brains than their younger counterparts, a given stroke volume in the elderly would affect a greater proportion of brain parenchyma, which may be a factor in the poorer neurological outcome [7]. Older populations also have a higher probability of having a history of prior strokes, which could impair their ability to recover from and make them more susceptible to additional injuries [8]. Additionally, several animal studies have shown that white matter vulnerability increases with age and could explain why post-ictus cognitive decline is higher in older populations [9–11].

### Prevalence of Comorbidities

Many common chronic conditions including essential hypertension, coronary artery disease, atrial fibrillation, cardiovascular disease, and diabetes mellitus have a higher prevalence with increasing age [12], and as a result, may confound the attributable risk of age with regards to the odds of having an ICH and the outcomes in patients who survive. Hypertension is a widely identified risk factor for ICH [13–16]—a meta-analysis by Jackson et. al. showed that essential hypertension increases the risk of ICH by approximately two-fold [17], and another study estimated that 83% of ICH patient carry the diagnosis of essential hypertension [18]. Additionally, although atrial fibrillation is primarily a risk factor for cardio embolic stroke [19], this patient population is routinely anti coagulated with agents such as warfarin, which may increase the risk of ICH by two to fivefold in a dose-dependent manner [20–22]. In patients who survive the initial ICH, certain studies have shown that those with other comorbidities, such as diabetes and peripheral vascular disease, have a higher 30-day and 1-year mortality, as well as worse functional outcome [23,24]. Moreover, Pooled data of case-control studies showed that diabetic individuals are 1.3 times more likely than non-diabetics to develop ICH [13]. While diabetes has been identified as a weak risk factor, perhaps the pathogenesis of disease, with both microvascular and macrovascular changes developing over time, increases susceptibility of ICH.

Additionally, a review of the literature indicates other risk factors including alcohol use and smoking history as potential predictors of ICH [13]. The prevalence of multi morbidity, namely vascular diseases, greatly increases with age and has been found to be present in most people age 65 or older, contributing to higher mortality and reduced functional status, possibly worsening outcomes of ICH [25–28]. In effect, comorbidities likely have varying degrees of influence on

the risk of having an ICH and on the functional outcome. However, it is the potential, and likely, culmination of synergy when they act together in the elderly population that could greatly account for the higher incidence and mortality rates seen in this population.

### Prognosis

Understanding the independent predictors associated with aging that lead to worse mortality rates and prognoses, such as comorbidities and treatment options, could allow for more effective interventions and reductions in unfavorable outcomes. Factors predicting mortality at 30 days and 1 year include age, cognitive function upon admission, hematoma volume, intra ventricular extension of hematoma, infratentorial location of hematoma, and heart disease [29]. Many of these known risk factors influence each other but after accounting for other variables, age is an independent predictor [30]. Table 1 explores the impact of age on prognosis of ICH morbidity and mortality and characterizes age and ICH outcomes in several well-known studies. Examination of these findings indicates that older age is associated with increased mortality, worse functional outcomes, and decreased long-term survival. As shown in Table 1, the ages most commonly used as a cut-off in the literature range from 60–80 years of age, with the majority being either 65 or 70 years of age.

One study that examined long-term prognosis in survivors after an initial ICH demonstrated that they had persistently increased mortality rates during long-term follow up compared with the general population [31]. They also found that increased age, diabetes mellitus, and anticoagulation therapy at onset of ICH were independent predictors of death among the survivors [31]. Possible explanations for this observation include comorbidities of vascular diseases such as hypertension, atherosclerosis, and cerebral amyloid angiopathy, as discussed above [8,32].

### Aging and Other Issues

The weakened physiologic reserve, higher mortality rates, worse healing, worse long-term functional outcomes, and more debilitation with less insult is often seen in comparison to younger cohorts [33]. This reduction in physiologic reserve, the extra capacity of the body’s organ systems to overcome challenges, increases the susceptibility of older patients to injury, disease, and loss of function. In Pisani’s review article, many of the physiological changes associated with treating elderly populations are elucidated [34]. For instance, as

**Table 1:** Prognosis of Age in ICH Mortality and Morbidity.

Study	Year	Design	Age	Outcomes	
Kim KD, Change CH, Choi BY, Jung YJ. [28]	2014	Retrospective Cohort	67.87±11.82	Expired	
			60.63±13.39	Survived	
Tveiten A, Ljostad U, Mygland A, Naess H. [41]	2013	Cross Sectional Study	78.3 mean age	Expired	
			70.8 mean age	Survivors	
			67.3 mean age	Independent functioning	
Sun W, Pan W, Kranz PG, Hailey CE, Williamson RA, Sun W, Laskowitz DT, James ML. [29]	2013	Retrospective Cohort	78.3 mean age	Dependent functioning	
			Mean 65	Presence of late neurological deterioration	
			Range 52-75	No presence of later neurological deterioration	
Celikbilek A, Goksel BK, Zararsiz G, Benli S. [16]	2013	Retrospective Cohort	Mean 60	Mortality increased with age 65< (p=0.043.)	
			Range 48-71		Univariate OR=2.55 at 95% CI for mortality and age over 65 years (p=0.028);
			Mean 60		multivariate OR=2.85 at 95% CI for mortality and age over 65 years (p=0.035).
Fogelholm R, Nuutila M, Vuorela AL. [14]	1992	Prospective Cohort	>70	Age >70 years is the only identified factor independently associated with poor functional outcome.	

**Abbreviations:** CI: Confidence Interval; OR: Odds ratio

individuals age, their ability to respond to sympathetic stimulation declines, leading to failure of compensatory mechanisms such as increased maximal heart rate, ejection fraction and cardiac output. This puts them at an increased risk for vascular complications. A decrease in pulmonary function up to 50% can also be seen with older patients. Likewise, the kidneys also experience declining function due to the fact that approximately 40% of the nephrons become sclerotic between the ages of 25 and 85. Furthermore, renal blood flow decreases by half and the glomerular filtration rate declines to about 45% by the time an individual reaches 80 years of age. Medications will also have a different physiological effect. Hepatic blood flow diminishes by 30% between the ages of 30 and 75, and this alters the absorption, distribution, metabolism and excretion of medication. These factors culminate in age-related decline of organ system functions that cause an increased vulnerability to sepsis, changes in pharmacodynamics, and cognitive decline [34], all of which are contributing to disproportionate rates of complications, extended inpatient hospitalizations, and intensive care unit admissions in older cohorts compared to their younger counterparts. While a determined age at which these changes occur most frequently is still uncertain, the literature suggests that age does impact certain complication rates during inpatient hospitalizations after stroke [35].

### A self-fulfilling prophecy

Hospital management may also play a role in the differences in mortality and outcome between older and younger patients. Elderly patients tend to have more end-of-life care plans, including Do Not Resuscitate (DNR) orders, advanced care plans, and living wills. While studies indicate that there is not a difference in complication rates between elderly patients with ICH and younger ones [20], often times studies exclude patients over certain ages, which may skew the data.

As a result, it is possible that the nuances in management of ICH could be providing a selection bias, in that elderly patients with worse outcomes are less likely to receive intervention due to premeditated goals of care [36]. A recent study showed that patients who were treated more aggressively and transferred to specialist centers had better outcomes, yet interestingly it was younger patients that had higher transfer rates [37]. In this study, the odds of a patient being transferred decreased by 50% for every 10 year increase in age. After adjusting for prognostic factors, which included age, the authors stated that neurosurgical care remained strongly associated with a lower hazard of death while a DNR was associated with a higher hazard of death.

The role of DNRs in the mortality and morbidity of elderly patients is controversial. Some studies suggest that a DNR order could negatively impact the management and care [38], others have not found any such association [39]. Moreover, patients holding DNR orders tend to be associated with more severe strokes and increased age, which lead to higher mortality rates. These factors make it difficult to distinguish whether the findings are due to the stroke or a selection bias that precipitates withholding treatment options [40].

Elderly patients are also less likely to undergo surgical treatment, perhaps due to established end-of-life preferences or recommendations for treatment. Preliminary results, from the minimally invasive surgery and recombinant tissue-type plasminogen

activator in ICH evacuation phase II (MISTIE II) trial, demonstrated that clot evacuation and treatment were effective in reduction of Perihematoma Edema (PHE) [41]. However, the MISTIE II trial, did not include patients older than 75, making it difficult to extrapolate the data for older populations. Nevertheless, the role of PHE in ICH is important in regards to secondary neuronal injuries and has been implicated in worsening outcomes for patients with larger edema volume [42]; therefore the potential surgical treatment to improve outcomes is important in this population. While there are a myriad of factors involved in making a decision regarding treatment with surgical intervention for an individual, the decision to withhold this treatment in an elderly individual may be shifting the odds towards an unfavorable outcome.

### Conclusion

Aging carries numerous implications for the body, including changes to the cardiovascular system and central nervous system that interplay with multiple risk factors for ICH. Understanding the role of age in risk and outcomes of ICH can directly improve the planning of clinical trials and patient care. Identification of most commonly used age cut-off points in the literature can direct clinical practice. As assessed in this review, the literature suggests the age cut-off for mortality and morbidity to occur within the range of 60-80 years of age, with the most commonly used value of 65 or 70 years. Additionally, age increases the risk of multiple chronic health conditions and comorbidities, including hypertension, hypercholesterolemia, diabetes, and atrial fibrillation, which contribute to the pathology of ICH. These effects could also be exacerbated if the elderly populations have had these comorbidities for a longer period of time. The age-related interplay of these chronic conditions are highly likely to influence the risk of ICH, however, the mechanisms of interactions, extent of impact, and direction of causality are still uncertain.

### References

1. Brault M, Hootman J, Helmick CG, Thesis KA, Armour BS. Prevalence and common causes of disability among adults - United States, 2005. *Morb Mortal Wkly Rep.* 2009; 58: 421-426.
2. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. *Circulation.* 2012; 125: e2-e220.
3. Samson RD, Barnes CA. Impact of aging brain circuits on cognition. *Eur J Neurosci.* 2013; 37: 1903-1915.
4. Hemphill JC, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. *Stroke.* 2001; 32: 891-897.
5. Sonni S, Lioutas VA, Selim MH. New avenues for treatment of intracranial hemorrhage. *Curr Treat Options Cardiovasc Med.* 2014; 16: 277.
6. Brown WR, Thore CR. Review: cerebral microvascular pathology in ageing and neurodegeneration. *Neuropathol Appl Neurobiol.* 2011; 37: 56-74.
7. Gottesman RF, Kleinman JT, Davis C, Heidler-Gary J, Newhart M, Kannan V, et al. Unilateral neglect is more severe and common in older patients with right hemispheric stroke. *Neurology.* 2008; 71: 1439-1444.
8. Brott T, Thalinger K, Hertzberg V. Hypertension as a risk factor for spontaneous intracerebral hemorrhage. *Stroke.* 1986; 17: 1078-1083.
9. Hoffman WE, Pelligrino D, Miletich DJ, Albrecht RF. Brain metabolic changes in young vs aged rats during hypoxia. *Stroke.* 1985; 16: 860-863.
10. Asdaghi N, Butcher KS, Hill MD. Risks and benefits of thrombolysis in the elderly. *Int J Stroke.* 2012; 7: 142-149.

11. Baltan S, Besancon EF, Mbow B, Ye Z, Hamner MA, Ransom BR. White matter vulnerability to ischemic injury increases with age because of enhanced excitotoxicity. *J Neurosci*. 2008; 28: 1479-1489.
12. Blackman DK, Kamimoto LA, Smith SM. Overview: surveillance for selected public health indicators affecting older adults--United States. *MMWR CDC Surveill Summ*. 1999; 48: 1-6.
13. Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. *Stroke*. 2003; 34: 2060-2065.
14. Sacco RL. Risk factors, outcomes and stroke subtypes for ischemic stroke. *Neurology*. 1997; 49: S39-44.
15. Sturgeon JD, Folsom AR, Longstreth WT, Shahar E, Rosamond WD, Cushman M. Risk factors for intracerebral hemorrhage in a pooled prospective study. *Stroke* 2007; 38: 2718–2725.
16. Woo D, Sauerbeck LR, Kissela BM, Khoury JC, Szaflarski JP, Gebel J, et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. *Stroke*. 2002; 33: 1190-1195.
17. Jackson CA, Sudlow CL. Is hypertension a more frequent risk factor for deep than for lobar supratentorial intracerebral haemorrhage?. *J Neurol Neurosurg Psychiatry*. 2006; 77: 1244-1252.
18. Cheung RT, Zou LY. Use of the original, modified, or new intracerebral hemorrhage score to predict mortality and morbidity after intracerebral hemorrhage. *Stroke*. 2003; 34: 1717-1722.
19. Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. *Stroke*. 1996; 27: 1765-1769.
20. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. *Arch Intern Med*. 2004; 164: 880-884.
21. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. *Stroke*. 2005; 36: 1588-1593.
22. García-Rodríguez LA, Gaist D, Morton J, Cookson C, González-Pérez A. Antithrombotic drugs and risk of hemorrhagic stroke in the general population. *Neurology*. 2013; 81: 566-574.
23. Bar B, Hemphill JC. Charlson comorbidity index adjustment in intracerebral hemorrhage. *Stroke*. 2011; 42: 2944-2946.
24. Béjot Y, Aboa-Eboulé C, Hervieu M, Jacquin A, Osseby GV, Rouaud O, et al. The deleterious effect of admission hyperglycemia on survival and functional outcome in patients with intracerebral hemorrhage. *Stroke*. 2012; 43: 243-245.
25. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet*. 2012; 380: 37-43.
26. Gijzen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA. Causes and consequences of comorbidity: a review. *J Clin Epidemiol*. 2001; 54: 661-674.
27. Kadam UT, Croft PR, North Staffordshire GP Consortium Group. Clinical multimorbidity and physical function in older adults: a record and health status linkage study in general practice. *Fam Pract*. 2007; 24: 412-419.
28. Walker AE. Multiple chronic diseases and quality of life: patterns emerging from a large national sample, Australia. *Chronic Illn*. 2007; 3: 202-218.
29. Vermeer SE, Algra A, Franke CL, Koudstaal PJ, Rinkel GJ. Long-term prognosis after recovery from primary intracerebral hemorrhage. *Neurology*. 2002; 59: 205-209.
30. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. *Stroke*. 1993; 24: 987-993.
31. Hansen BM, Nilsson OG, Anderson H, Norrving B, Säveland H, Lindgren A. Long term (13 years) prognosis after primary intracerebral haemorrhage: a prospective population based study of long term mortality, prognostic factors and causes of death. *J Neurol Neurosurg Psychiatry*. 2013; 84: 1150–1155.
32. Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. *Lancet*. 2009; 373: 1632-1644.
33. Jacobs DG. Special considerations in geriatric injury. *Curr Opin Crit Care*. 2003; 9: 535-539.
34. Pisani MA. Considerations in caring for the critically ill older patient. *J Intensive Care Med*. 2009; 24: 83-95.
35. Chien-Min Chen, Hung-Chih Hsu, Chia-Hao Chang, Chu-Hsu Lin, Kai-Hua Chen, Wei-Chi Hsieh W-MC. Age-based prediction of incidence of complications during patient stroke rehabilitation: a retrospective longitudinal cohort study. *BMC Geriatr* 2014; 14: 41.
36. Zeevi N, Kuchel GA, Lee NS, Staff I, McCullough LD. Interventional stroke therapies in the elderly: are we helping? *AJNR Am J Neuroradiol*. 2012; 33: 638-642.
37. Kamran Abid, Andy Vail, Hiren Patel, Andrew King, Pippa Tyrrell AP-J. Which factors influence decisions to transfer and treat patients with acute intracerebral haemorrhage and which are associated with prognosis? A retrospective cohort study. *BMJ Open* 2013; 3.
38. Zahuranec DB, Brown DL, Lisabeth LD, Gonzales NR, Longwell PJ, Smith MA, et al. Early care limitations independently predict mortality after intracerebral hemorrhage. *Neurology*. 2007; 68: 1651–1657.
39. Jain A, Jain M, Bellolio MF, Scheers RM, Rabinstein AA, Ganti L. Is early DNR a self-fulfilling prophecy for patients with spontaneous intracerebral hemorrhage? *Neurocrit Care*. 2013; 19: 342-346.
40. Engelter ST, Reichhart M, Sekoranja L, Georgiadis D, Baumann A, Weder B, et al. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. *Neurology*. 2005; 65: 1795-1798.
41. Morgan T, Zuccarello M, Narayan R, Keyl P, Lane K, Hanley D. Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial. *Acta Neurochir Suppl*. 2008; 105: 147-151.
42. Appelboom G, Bruce SS, Hickman ZL, Zacharia BE, Carpenter AM, Vaughan K a, et al. Volume-dependent effect of perihematoma oedema on outcome for spontaneous intracerebral haemorrhages. *J Neurol Neurosurg Psychiatry*. 2013; 84: 488–493.